Femasys Doubles Enrollment Sites in FemBloc Pivotal Trial
Event summary
- Femasys Inc. has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States.
- New sites include Baylor Research Institute and Columbia University Medical Center, joining existing academic and private clinical practices.
- The trial is evaluating the safety and effectiveness of FemBloc, a non-surgical permanent birth control solution.
- FemBloc received regulatory approvals in Europe, the UK, and New Zealand in 2025.
The big picture
Femasys' expansion of enrollment sites in the FemBloc FINALE Pivotal Trial marks a significant step in its U.S. regulatory strategy. The inclusion of prominent academic centers underscores growing clinical interest in non-surgical permanent birth control solutions. This move is part of a broader trend towards innovative, less invasive reproductive health options, which could reshape the market dynamics for permanent birth control.
What we're watching
- Regulatory Strategy
- Whether Femasys can leverage European approvals and U.S. trial data to accelerate FDA approval for FemBloc.
- Clinical Trial Execution
- The pace at which Femasys can enroll and complete the FINALE trial, given the expanded site network.
- Market Adoption
- How post-market real-world data from Europe will support broader adoption of FemBloc globally.
